Patients
Physicians
Sponsors
Oncologists
About Us
News
ENG
Last updated 23 days ago
Share
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
492 patients around the world
Available in
Spain, Argentina, United States
Pfizer
1
Research sites
492
Patients around the world
This study is for people with
Multiple myeloma
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Inclusion criteria
Exclusion criteria
Sites
Hospital Universitario Austral - Pilar
View site
Av. Juan Domingo Perón 1500, Pilar, Buenos Aires
Hospital Universitario Austral - Pilar
View site
Av. Juan Domingo Perón 1500, Pilar, Buenos Aires
See details
Contact us
Contact us
Sponsor
Pfizer
Conditions
Multiple myeloma
Requirements
From 18 Years
All Gender
Unique study ID
clinicaltrials.gov
NCT06152575
About us
Our mission
Our team
Partners
FAQs
Medical news
Latest news
Studies
Interviews
Testimonials
Products
UEPM Onco
UEPM Physicians
Links
Downloads
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent
English
Terms and Conditions
Privacy Policy
Change your consent